Home' Australian Pharmacist : Australian Pharmacist November 2016 Contents Australian Pharmacist November 2016 I ©Pharmaceutical Society of Australia Ltd.
proportion of patients adhering to their new medicine
by about 10% compared with normal practice.
intervention consisted of one consultation 7–14 days
after initial prescription followed by another 14–21
days thereafter to identify problems with treatment and
provide support if needed.
Lung Foundation Australia has a number of resources
for pharmacists, including patient handouts with
instructions on inhaler technique, and also offers an
online training program on COPD for pharmacists – COPD
The training has been developed
in consultation with peak pharmacy organisations
including the Pharmaceutical Society of Australia, COPD
clinical experts and community pharmacists. Other
resources include a listing of locations for pulmonary
rehabilitation and pulmonary maintenance exercise
programs. Visit: www.lungfoundation.com.au
In summary, there is good evidence supporting the role
of pharmacists in the care for patients with COPD to
achieve better health outcomes. This work encompasses
pharmacotherapy and non-pharmacotherapy including
recommendations to attend effective programs such as
1. Wagner EH. The role of patient care teams in chronic disease management. British
Medical Journal. 2000;320(7234):569.
2. Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US
Pharmacists’ Effect as Team Members on Patient Care: Systematic Review and Meta-
Analyses. Medical Care. 2010;48(10):923–33 .
3. Page A, Abrose S, Glover J et al. Atlas of Avoidable Hospitalisations in Australia:
ambulatory care-sensitive conditions. Adelaide PHIDU. University of Adelaide. 2007.
4. Institute for Health Metrics and Evaluation 2013. Global Burden of Disease,
Visualizations, GBD Arrow Diagram. Seattle: Institute for Health Metrics and
5. Toelle BG, Xuan W, Bird TE, Abramson MJ, Atkinson DN, Burton DL, et al. Respiratory
symptoms and illness in older Australians: the Burden of Obstructive Lung Disease
(BOLD) study. Med J Aust. 2013;198(3):144–8 .
6. Yang IA, Dabscheck E, George J, Jenkins S, McDonald CF, McDonald V, Smith B, Zwar
N. The COPD-X Plan: Australian and New Zealand Guidelines for the management of
Chronic Obstructive Pulmonary Disease 2016. Version 2.46, Jun 2016.
7. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831–8 .
8. Sulaiman I, Seheult J, MacHale E, D’Arcy S, Boland F, McCrory K, et al. Irregular and
Ineffective: A Quantitative Observational Study of the Time and Technique of Inhaler
Use. J Allergy Clin Immunol Pract. 2016;4(5):900–9.e2.
9. Hesso I, Gebara SN, Kayyali R. Impact of community pharmacists in COPD
management: Inhalation technique and medication adherence. Respir Med.
10. Axtell S, Haines S, Fairclough J. Effectiveness of various methods of teaching proper
inhaler technique: The importance of pharmacist counseling. J Pharm Pract. 2016.
11. Basheti IA, Armour CL, Bosnic-Anticevich SZ, Reddel HK. Evaluation of a novel
educational strategy, including inhaler-based reminder labels, to improve asthma
inhaler technique. Patient Educ Couns. 2008;72(1):26–33 .
12. Xin C, Xia Z, Jiang C, Lin M, Li G. The impact of pharmacist-managed clinic on
medication adherence and health-related quality of life in patients with COPD: a
randomized controlled study. Patient Prefer Adherence. 2016;10:1197–203.
13. Suhaj A, Manu MK, Unnikrishnan MK, Vijayanarayana K, Mallikarjuna Rao C.
Effectiveness of clinical pharmacist intervention on health-related quality of life in
chronic obstructive pulmonary disorder patients - a randomized controlled study. J
Clin Pharm Ther. 2016;41(1):78–83.
14. Elliott RA, Boyd MJ, Salema NE, Davies J, Barber N, Mehta RL, et al. Supporting
adherence for people starting a new medication for a long-term condition through
community pharmacies: a pragmatic randomised controlled trial of the New
Medicine Service. BMJ Qual Saf. 2015.
15. Lung Foundation Australia. Available at: http://lungfoundation.com.au/health-
professionals/pharmacy/. Accessed Oct 4, 2016.
Please review Product Information before recommending.
Full Product Information is available on request from Aspen
Pharma or by visiting www.aspenpharma.com.au/products
Minimum Product Information: Chlorsig (chloramphenicol) eye drops (0.5%) and ointment
(1%) Indications: For the treatment of bacterial conjunctivitis. Other superficial ocular infections
caused by chloramphenicol-sensitive organisms under medical supervision only. Contraindications:
Hypersensitivity to any excipients and or/toxic reaction to the drug. Precautions: Bone marrow
hypoplasia, including aplastic anaemia and death, has been rarely reported following local application of
chloramphenicol. Chloramphenicol should not be used when less potentially dangerous agents would be
expected to provide effective treatment. Ophthalmic agents may retard corneal wound healing. Eye pain/
injury, reduced or blurred vision, severe ocular infections, contact lenses, dry eye syndrome, glaucoma,
concomitant use of other ocular medications, eye surgery or laser within the last 6 months, pregnancy
(Cat A), lactation. See full PI. Adverse Reactions: Blood dyscrasias; local irritation (itching/burning),
angioneurotic oedema; anaphylaxis, urticaria, fever, vesicular, maculopapular dermatitis. Dosage and
Administration: Eye Drops: Adults and children (2 years and over): Instil 1 or 2 drops in the affected eye(s)
every two to six hours for up to 5 days. Eye Ointment: Adults and children (2 years and over): Apply 1.5 cm
into lower eye lid of the affected eye every three hours for up to 5 days. Chlorsig is not recommended for
children under 2 years except on medical advice. See full PI. (PI last amended Oct 2010). References:
1. Chlorsig Product Information Oct 2010. 2. Australian Pharmaceutical Index IMS Health Australia May
2016. Aspen Australia is comprised of Aspen Asia Pacific Pty Ltd (ABN 75 146 444 484) and its
subsidiaries, including Aspen Pharmacare Australia Pty Ltd (ABN 51 096 236 985), Aspen Pharma Pty
Ltd (ABN 88 004 118 594), Aspen Nutritionals Australia Pty Limited ACN 160607509, Orphan Holdings
Pty Ltd (ABN 50 115 816 209), Orphan Australia Pty Ltd (ABN 11
067 189 342) and Aspen Products Pty Ltd (ABN 17 003 144 170).
All sales and marketing requests to: Aspen Pharma Pty Ltd,
34-36 Chandos Street, St Leonards NSW 2065. Tel 02 8436 8300
| www.aspenpharma.com.au | firstname.lastname@example.org |
Date prepared July 2016. TAPH0054. ASP1359.
This product is not listed on the PBS.
Australia’s most trusted treatment
for bacterial conjunctivitis
Stick with Chlorsig
for treatment choice 1*
Drops and ointment*
Links Archive Australian Pharmacist October 2016 Australian Pharmacist December2016 Navigation Previous Page Next Page